CAM Study for Hematologic Malignancies, France, NCT07541326
ClinicalTrials.gov Studies
Summary
NIH's ClinicalTrials.gov has registered study NCT07541326, an observational study examining the use of complementary and alternative medicine (CAM) among patients with hematologic malignancies in France. The study uses a questionnaire-based approach to collect data on CAM prevalence, types, and purposes among this patient population. Hematologic malignancies are underrepresented in existing CAM research, with a 2015 French study showing only 2% hematologic cases among all cancer types surveyed.
What changed
NIH's ClinicalTrials.gov registry has added study NCT07541326, a new observational research project on complementary and alternative medicine (CAM) use among patients diagnosed with hematologic malignancies in France. The study will collect data via questionnaire on CAM prevalence, types, and motivations among this patient group, addressing a gap identified in prior French cancer research where hematologic malignancies comprised only 2% of cases. The study's abstract references a 2015 French study showing 83% CAM use across all cancer types, indicating high baseline interest in these therapies among cancer patients.
For compliance officers and healthcare researchers, this registry entry reflects growing research interest in CAM integration within oncology care. While the study itself does not impose regulatory obligations, it may generate data relevant to healthcare providers offering or considering CAM services for hematologic cancer patients. Clinical trial sponsors conducting similar research should ensure compliance with applicable clinical trial registration requirements.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France
N/A NCT07541326 Kind: NA Apr 21, 2026
Abstract
Integrative medicine promotes the incorporation of elements from complementary and alternative medicines (CAM) into patient care. These approaches are defined as treatments that are not routinely part of conventional medical care (1). CAM practices include osteopathy, acupuncture, aromatherapy, naturopathy, and various energy-based techniques, although their efficacy is not always well-established. Nevertheless, a meta-analysis on the use of CAM in the context of cancer reported a 40% prevalence of use in 2012 (2). Subsequently, a study conducted in France in 2015 revealed an 83% prevalence of CAM use across all types of cancer, underscoring the interest in these therapies (3). CAM is often employed to alleviate side effects of conventional treatments, such as fatigue, nausea, and vomiting. The 2015 French study primarily focused on solid tumors, with hematological malignancies representing only 2% of the cases, thereby limiting the assessment of CAM use in this context (3). Currently, there is no specific data evaluating the use of CAM among patients with hematological malignancies in France.
Hematological malignancies, unlike solid tumors, are characterized by their diffuse nature, making their localization and treatment more challenging for patients to comprehend (4). Additionally, a qualitative study the investigators conducted on the spiritual needs of patients recently diagnosed with hematological malignancies identified CAM as an area of interest. Among the ten pat...
Conditions: Hematological Malignancies
Interventions: Questionnaire on Complementary and Alternative Medicines (CAM)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.